DRG Market Assessment reports

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…

The PsA therapy market is undergoing significant transformation with the emergence of new treatment options, intensifying competition for favorable payer coverage. TNF-α inhibitors, such as AbbVie…

With the introduction of extended-duration therapies like Roche’s Vabysmo and Regeneron’s Eylea HD, the U.S. market for wet age-related macular degeneration (AMD) is undergoing significant changes…

Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…

Until recently, approved treatments for Alzheimer’s disease (AD) primarily consisted of approved procognitive symptomatic drugs (e.g., donepezil, memantine), as well as off-label antidepressants…

Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…

Diabetic macular edema (DME), a complication of diabetic retinopathy caused by persistently high blood sugar levels, can lead to vision loss if untreated. VEGF inhibitors such as Eylea, Lucentis,…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious CNS and renal manifestations…

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…

TNF-alpha inhibitors (e.g., Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira) are entrenched in the U.S. ulcerative colitis (UC) therapy market. Alternative treatment options…

NMOSD is a rare, chronic neuroinflammatory disorder marked by optic neuritis and longitudinal extensive transverse myelitis, often leading to repeated attacks and accumulating neurological damage…